Psilocybin Extends Cellular Lifespan and Boosts Survival in Aged Mice, Nature Study Finds

What Did the Psilocybin Longevity Study Actually Show?

The research, published in npj Aging under the Nature portfolio, examined whether psilocybin — the serotonergic psychedelic compound best known for treating depression — could influence biological aging. In cultured human cells, psilocybin exposure was associated with a measurable extension of cellular lifespan, as assessed by the number of divisions a cell undergoes before entering senescence.

When administered to aged mice, psilocybin-treated animals showed improved survival compared with controls. The investigators also reported changes in markers associated with oxidative stress and cellular senescence, both of which are considered hallmarks of aging in the geroscience framework established by Carlos López-Otín and colleagues.

How Could a Psychedelic Drug Affect Aging?

Psilocybin is rapidly metabolized to psilocin, which binds 5-HT2A and related serotonin receptors throughout the brain and peripheral tissues. Beyond its well-documented effects on mood, mounting research suggests that activating these receptors can influence gene expression related to synaptic plasticity, neurotrophic signaling, and cellular stress responses.

Aging biology increasingly focuses on shared upstream drivers — chronic inflammation, mitochondrial dysfunction, impaired proteostasis, and cellular senescence. If psychedelic compounds can tune some of these pathways, even modestly, it would align with a broader shift in longevity science away from disease-by-disease treatment and toward targeting aging itself. Similar logic underlies research into metformin, rapamycin, and senolytic drugs.

Does This Mean Psilocybin Will Help Humans Live Longer?

Mouse lifespan studies have historically been poor predictors of human outcomes. Compounds such as resveratrol and various antioxidants showed striking effects in rodents but have not produced meaningful lifespan extension in humans. Regulatory agencies including the FDA do not currently recognize aging as a treatable indication, meaning any future trials would likely target specific age-related conditions rather than longevity directly.

Psilocybin itself remains a Schedule I substance in the United States, though the FDA has granted Breakthrough Therapy designation for its use in treatment-resistant depression. Experts caution against self-experimentation: doses used in controlled research settings are carefully calibrated, supervised, and paired with psychological support. The new findings should be read as a provocative hypothesis-generating result, not a clinical recommendation.